e In a prospective study of solid-organ transplant recipients (n ‫؍‬ 22; 15 hepatic and 7 renal) receiving valganciclovir for cytomegalovirus (CMV) prophylaxis, electronic estimation of glomerular filtration rate (eGFR) underestimated the true GFR (24-h urine creatinine clearance) by >20% in 14/22 (63.6%). Its use was associated with inappropriate underdosing of valganciclovir, while the Cockroft-Gault equation was accurate in 21/22 patients (95.4%). Subtherapeutic ganciclovir levels (<0.6 mg/liter) were common, occurring in 10/22 patients (45.4%); 7 had severely deficient levels (<0.3 mg/liter).
S
uppressive antiviral therapy with valganciclovir (VGCV) has greatly reduced the risk of cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients, but ganciclovir (GCV)-resistant isolates are increasingly being reported (1, 2) . VGCV dosing is routinely guided by renal function (3) . The etiology of breakthrough CMV disease is often multifactorial but may be related to subtherapeutic levels of GCV (2) .
Due to a perceived increase in breakthrough CMV viremia and cases of GCV-resistant CMV at our institution, we assessed the accuracy of surrogate estimates of glomerular filtration rate (GFR) and correlated these with VGCV dosing and serum GCV levels.
All adult hepatic and renal SOT recipients receiving VGCV for CMV prophylaxis at our hospital during the 6 months from March 2011 were identified from the transplant databases. Patients living in rural settings in which GCV levels could not be reliably processed were excluded. The project was approved by the institution's Ethics Committee.
The following demographic data were collected: age, gender, weight, hemoglobin, VGCV and immunosuppressant doses, and CMV serological status. Renal function was assessed using four approaches: serum creatinine, estimated GFR (eGFR) by the routinely reported "modification of diet in renal disease" formula (4), the Cockroft-Gault (C-G) equation (5), and measured creatinine clearance (mCCl) by 24-h urine collection. We defined mCCl as the gold standard estimate of true CCl.
Patients underwent routine posttransplant care and monitoring at the discretion of their physician, with VGCV prophylaxis recommended for 6 months posttransplant in high-risk patients and standard VGCV dose adjustments based on CCl (3). We assessed whether estimates of CCl (eGFR or C-G) led to alterations of VGCV dose for each patient.
Trough (predose) serum GCV levels were assessed using highperformance liquid chromatography (6) at least once for all patients and more frequently if there was a change in dosing. GCV levels were defined as therapeutic (Ͼ0.6 mg/liter), subtherapeutic (Յ0.6 mg/liter), or severely deficient (Ͻ0.3 mg/liter) (7, 8) . Renal function (eGFR, C-G, and mCCl) was assessed whenever GCV levels were measured.
Patients underwent weekly CMV viral load (VL) monitoring.
Samples were processed at a single laboratory using a whole-blood assay modified according to the method of Sanchez et al. (9) (lower limit of detection 10 copies/ml). Samples with a CMV VL of Ͼ1,000 copies/ml were assessed for GCV resistance, which was defined as laboratory proven (PCR detection of mutations in the UL97 or UL54 gene known to be associated with resistance) or clinically suspected (persistent CMV viremia for Ͼ21 days despite intravenous GCV without a resistance mutation detectable) (10).
The results were summarized with differences assessed using paired t test or Fisher's exact test, as appropriate. Statistical significance was regarded as a two-tailed P value of Ͻ0.05. All analyses were performed using Stata 11.2/IC (College Station, TX).
Patient characteristics and results are shown in Table 1 . Among 40 SOT patients identified, 22 satisfied the study criteria (15 hepatic and 7 renal), while 18 were excluded (12 no longer taking VGCV and 8 living in a distant rural setting). A total of 38 GCV levels were assessed (11 patients were assessed once, and 11 others 2 or 3 times), with detailed renal function analysis undertaken on 31/38 episodes.
Overall, eGFR underestimated mCCl by Ͼ20% in 63.6% of patients (14/22) and potentially resulted in 45.4% of patients (10/ 22; 5 confirmed and 5 at risk) having their VGCV dose inappropriately reduced (Fig. 1) . Among the 31 episodes of detailed renal analysis, the mean intrapatient difference between eGFR and mCCl was Ϫ20.2 mmol/liter (95% confidence interval [CI], 8.52 to 31.92; P ϭ 0.014). In comparison, the C-G estimate of renal function appeared very comparable to the mCCl, with a difference of Ϫ3.0 mmol/liter (95% CI, Ϫ9.70 to 5.92; P ϭ 0.625). If clinicians had used the C-G estimate for renal function, appropriate VGCV dosing would have been prescribed in 95.4% of patients (21/22).
Subtherapeutic GCV levels were observed in 10/22 patients (45.4%) at some time during the study, with 70% of these (7/10) being severely deficient. Four of these 10 patients were receiving inappropriately reduced doses of VGCV due to perceived renal impairment based on eGFR (Fig. 2) , with a further 3 patients receiving reduced dosing that was appropriate according to current recommendations.
Eleven of the 22 patients (35/89 assessments [39.3%]) were CMV viremic at some stage during the study period, with 4 patients noted to have a CMV viral load of Ͼ1,000 copies/ml. On most occasions (28/35 [80.0%]), the viremia was low grade (log 1 to 3 copies/ml), but in 7/35 (20.0%), it was Ͼlog 3 copies/ml. There was, overall, poor correlation between GCV levels and detection of CMV viremia (Fig. 2) . We identified one laboratoryproven and one clinically suspected case of GCV-resistant CMV; the GCV levels in these patients were 0.9 and 0.5 mg/liter, respectively.
Prevention of CMV disease through optimization of VGCV dosing is a crucial component of posttransplant care (2), yet appropriate dosing is not straightforward among patients with abnormal or changing renal function, both of which are common following SOT. Although radionuclide methods are often considered the gold standard for accurately measuring GFR, they are impractical for daily clinical use, while other methods that are based on serum cystatin-C or creatinine (such as the modification of diet in renal disease formula [MDRD, or eGFR], C-G, and the chronic kidney disease epidemiological collaboration [CKD-EPI] equations) are more frequently used by clinicians (11, 12) . In this study, we focused on the eGFR and C-G equations, as they are the two most common methods by which GFR is estimated in Australia. Our findings raise serious doubts regarding the accuracy of eGFR as a useful estimate of true GFR in the transplant setting, as it underestimated mCCl by Ͼ20% in two-thirds of patients, potentially leading to underdosing of VGCV in 45.4%. The minimum GCV trough concentration required to prevent CMV viremia and disease are not well defined. Based on previous studies largely assessing CMV disease prevention in HIV-infected patients, we classified levels of Յ0.6 mg/liter as subtherapeutic (8) . For non-HIV immunosuppressed populations, such as SOT recipients, Erice et al. (13) found that patients who did not have CMV disease had mean GCV trough levels of 0.7 g/ml, compared with 0.43 g/ml in those with progressive CMV. Nevertheless, the GCV level that is required to avoid asymptomatic CMV viremia posttransplantation, as was the case with the vast majority of our study population, is uncertain.
Although we did not detect a clear relationship between GCV levels and CMV viremia, this was potentially influenced by the complex interplay between the patients' net degree of immunosuppression, other host-specific factors, and the specific viral strain (or strains) involved, as well as the VGCV dosing (10) . Based on our relatively small study, it would seem that GCV concentrations of Յ0.6 mg/liter are common (45.4% at some stage), with a worrisome number of patients with severely low levels observed (below the routinely reported 50% inhibitory concentration [IC 50 ] for CMV) (7), yet for most patients, this was not associated with viremia.
A recent meta-analysis has proposed that 450 mg VGCV daily is not inferior to the currently recommended 900 mg (14) . However, this analysis did not include pharmacodynamic data or data from randomized trials directly comparing the two doses. Chamberlain et al. (15) reported that among renal transplant recipients treated with 450 mg VGCV daily, the trough GCV concentration was less than half that achieved with a 900-mg dose and tended to be below 0.6 g/ml. Although further research is needed to determine if there is a relationship between ganciclovir levels and clinical outcomes, it is plausible that the widespread use of 450 mg VGCV daily may expose a large number of patients to potentially subtherapeutic GCV levels.
Our study has some limitations, including a single-center observational design and relatively small sample size, therefore limiting our ability to control for the impact of specific immunosuppressant regimens on CMV viremia and the development of GCV resistance.
We believe our findings raise important questions regarding the accuracy of eGFR in SOT recipients and caution against its routine use to guide VGCV dosing in this patient population, in whom low GCV levels may have major clinical implications. We therefore recommend that clinicians use an alternative estimate of GFR, such as the C-G equation or mCCl, to guide VGCV dosing in SOT recipients and that therapeutic drug monitoring of GCV may be worthwhile. Further research is needed in this important area.
